Variety of qualified sufferers: CDEC reviewed the uncertainty in the volume of people with reasonably intense to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific gurus consulted by CADTH indicated that some people who will be categorised as acquiring delicate or reasonable condition could have a significant bleeding